81256-89-5

Basic information

• Product Name: N2-isobutyryl-5'-O-(4,4'-dimethoxytrityl)-3'-O-tert-butyldimethylsilyl guanosine
• Synonyms: N2-isobutyryl-5'-O-(4,4'-dimethoxytrityl)-3'-O-tert-butyldimethylsilyl guanosine;5'-DMT-3'-TBDMS-ibu-rG;3'-O-tert-Butyldimethylsilyl-5'-O-DMT-N2-isobutyrylguanosine
• CAS NO: 81256-89-5
• Molecular Formula: C₄₁H₅₁N₅O₈Si
• Molecular Weight: 769.95784
• Mol File: 81256-89-5.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Density: 1.25±0.1 g/cm3(Predicted)
• PKA: 9.16±0.20(Predicted)
• CAS DataBase Reference: N2-isobutyryl-5'-O-(4,4'-dimethoxytrityl)-3'-O-tert-butyldimethylsilyl guanosine(CAS DataBase Reference)
• NIST Chemistry Reference: N2-isobutyryl-5'-O-(4,4'-dimethoxytrityl)-3'-O-tert-butyldimethylsilyl guanosine(81256-89-5)
• EPA Substance Registry System: N2-isobutyryl-5'-O-(4,4'-dimethoxytrityl)-3'-O-tert-butyldimethylsilyl guanosine(81256-89-5)

Safety Data

• Hazardous Substances Data: 81256-89-5(Hazardous Substances Data)

Usage

General Description

N2-isobutyryl-5'-O-(4,4'-dimethoxytrityl)-3'-O-tert-butyldimethylsilyl guanosine is a chemical compound that belongs to the class of nucleosides. It is a modified form of guanosine, containing an isobutyryl group at the N2 position and protecting groups at the 5’ and 3’ positions. The 4,4'-dimethoxytrityl group at the 5’ position and the tert-butyldimethylsilyl group at the 3’ position serve to protect these functionalities in synthetic processes. N2-isobutyryl-5'-O-(4,4'-dimethoxytrityl)-3'-O-tert-butyldimethylsilyl guanosine is commonly used in the synthesis of oligonucleotides, particularly in the preparation of modified nucleic acid analogs for use in research and medical applications. Its specific structural modifications allow for enhanced stability and functionality in nucleic acid-based technologies.

Upstream product

• 118-00-3 G 
• 64350-24-9 N²-isobutyryl-2'-deoxyguanosine 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 81246-83-5 9-(5-O-dimethoxytrityl-β-D-ribofuranosyl)-2-N-isobutyrylguanine 

Downstream Products

• 1187644-22-9 N₂-isobutyryl-5'-O-(4,4'-dimethoxytrityl)-3'-O-tertbutyldimethylsilyl-2'-sulfamoyl-guanosine 
• 1187644-14-9 N₂-isobutyryl-5'-O-(4,4'-dimethoxytrityl)-3'-O-tertbutyldimethylsilyl-2'-O-(2-cyanoethyl)-phosphonate guanosine 
• 201667-44-9 N-(9-{(2R,3R,4R,5R)-5-[Bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-4-hydroxy-3-methylsulfanylmethoxy-tetrahydro-furan-2-yl}-6-oxo-6,9-dihydro-1H-purin-2-yl)-isobutyramide 
• 201667-38-1 N-{9-[(2R,3R,4R,5R)-5-[Bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-4-(tert-butyl-dimethyl-silanyloxy)-3-methylsulfanylmethoxy-tetrahydro-furan-2-yl]-6-oxo-6,9-dihydro-1H-purin-2-yl}-isobutyramide 

Relevant articles and documents

CYCLIC DINUCLEOTIDES AS STING AGONISTS

Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R, R1B, R1C, R2B

ppGpp analogues inhibit synthetase activity of Rel proteins from Gram-negative and Gram-positive bacteria

A prominent feature of the stringent response is the accumulation of two unusual phosphorylated derivatives of GTP and GDP (pppGpp: 5′-triphosphate-3′-diphosphate, and ppGpp: 5′-3′-bis-diphosphate), collectively called (p)ppGpp, within a few seconds after the onset of amino-acid starvation. The synthesis of these 'alarmone' compounds is catalyzed by RelA homologues. Other features of the stringent response include inhibition of stable RNA synthesis and modulation of transcription, replication, and translation. (p)ppGpp accumulation is important for virulence induction, differentiation and antibiotic resistance. We have synthesized a group of (p)ppGpp analogues and tested them as competitive inhibitors of Rel proteins in vitro. 2′-Deoxyguanosine-3′-5′-di(methylene bisphosphonate) [compound (10)] was found as an inhibitor that reduces ppGpp formation in both Gram-negative and Gram-positive bacteria. In silico docking together with competitive inhibition analysis suggests that compound (10) inhibits activity of Rel proteins by competing with GTP/GDP for its binding site. As Rel proteins are completely absent in mammalians, this appears to be a very attractive approach for the development of novel antibacterial agents.